SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's inches up on launching Abiraterone Acetate Tablets in US market

19 Jun 2020 Evaluate

Dr. Reddy's Laboratories is currently trading at Rs. 4008.55, up by 3.80 points or 0.09% from its previous closing of Rs. 4004.75 on the BSE.

The scrip opened at Rs. 4030.00 and has touched a high and low of Rs. 4044.90 and Rs. 3994.00 respectively. So far 14166 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4189.35 on 10-Jun-2020 and a 52 week low of Rs. 2352.00 on 14-Aug-2019.

Last one week high and low of the scrip stood at Rs. 4127.20 and Rs. 3954.20 respectively. The current market cap of the company is Rs. 66484.06 crore.

The promoters holding in the company stood at 26.75%, while Institutions and Non-Institutions held 44.50% and 14.65% respectively.

Dr. Reddy's Laboratories has launched Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the US Food & Drug Administration (USFDA). The Zytiga brand and generic market had U.S. sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health. The company’s Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

 

Dr. Reddys Lab Share Price

1293.25 -13.55 (-1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×